Study Design: This interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning neither participants nor the care providers, investigators, or outcome ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic ...

An expert discusses how the PEACE III combination of radium-223 and enzalutamide represents an effective treatment option for the limited population of patients who reach first-line metastatic ...

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor signalling inhibitor Xtandi (enzalutamide) in a subset of prostate cancer patients.

Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on ...

CMS proposes the 2026 Physician Fee Schedule, addressing payment disparities in oncology, but warns of financial threats from ...

Corcept Therapeutics CORT announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its lead pipeline candidate, relacorilant, for treating a new indication. The ...